News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

UK Cancer Drugs Fund Adds Roche (RHHBY), Celgene Corporation (CELG) And Exelixis, Inc. (EXEL) Drugs



3/24/2014 8:15:53 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Three new drugs have been added to the Cancer Drugs Fund (CDF) in a move NHS England says could benefit 900 patients per year. The Fund will add new NHS coverage in England for Roche's Avastin (bevacizumab), Celgene's Abraxane (albumin bound paclitaxel) and Exelixis' Cometriq (cabozantinib). The CDF provides special funding for drugs that have clinical demand, but haven't been backed by England's cost effectiveness watchdog NICE, and in its first year saw particularly strong demand for Avastin.

Help employers find you! Check out all the jobs and post your resume.



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES